Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education Program - COLT Meeting 2018 (Session 5)

 

Timothy Hughes                            

 

 Deborah White Agnes YONG w labcoat1              

 

Session 5: The CML frontier
Chair: Dr David Yeung

  • Making TFR Mainstream
    (Prof. Tim Hughes)
  • Prognostic biomarkers in CML
    (Prof. Deborah White)
  • The immunology of CML and immunomodulation
    (A/Prof Agnes Yong)

 

Virtual Education Program - COLT Meeting 2018 (Session 4)

 

David Ross

 

 Devendra Hiwase Michael Osborn              

 

Session 4: CML Related Topics
Chair: A/Prof Agnes Yong

  • Management of Myelofibrosis
    (Dr David Ross)
  • MDS/MPN Overlap Syndrome
    (Dr Devendra Hiwase)
  • Pediatric CML
    (Dr Michael Osborn)

 

Virtual Education Program - COLT Meeting 2018 (Session 3)

 

Susan Branford

 

 David Ross David Yeung 3                  

  

Session 3: TFR in CML
Chair: Dr David Ross

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • TFR in CML - Clinical Trial Update
    (Dr David Ross)
  • Response definitions and endpoint determination 
    in CML clinical trials
    (Dr David Yeung)

 

Virtual Education Program - COLT Meeting 2018 (Session 2)

 

Susan BranfordAgnes YONG w labcoat1  

 

                                        

 

Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

  • Molecular monitoring in CML
    (A/Prof Susan Branford)
  • Allograft - still a role in CML?
    (A/Prof Agnes Yong)

 

Virtual Education Program - COLT Meeting 2018 (Session 1)

-- Virtual Education Program: 2018 Edition

 

Presentations from the COLT Meeting 2018

We are pleased to make available a series of presentations from the COLT Meeting 2018, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, practicalities on CML management, TFR in CML, CML related topics and the CML frontier.

Timothy Hughes.pngDavid Yeung 3Devendra Hiwase

 

 

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • CML - current clinical issues
    and future directions 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

EHA 2018: TFR - a new goal for CP-CML patients (Delphine Réa)

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Réa


TFR - a new treatment goal of CP-CML patients?
Dr Delphine Réa, Centre-Hospitalo-Universitaire Saint-Louis, Paris, France 

  • Lessons from clinical trials: TKI discontinuation in CP-CML is feasible
  • Deep-molecular responses: definitions
  • Clinical practice: patient case
  • Deep-molecular responses during 1st line TKI treatment
  • TKI discontinuation in CP-CML: transition from trials to standard practice
  • TKI withdrawal syndrome during the treatment-free phase
  • Recommendations for standard practice: definitions and management of relapses
  • Conclusion 1: Evolving treatment goals
  • Conclusion 2: TKI discontinuation in standard practice
We are very grateful for the support of Brandcast media to produce these webstreams.